Talquetamab not checked
Johnson & Johnson (Janssen) · JNJ-64407564 · CD3xGPRC5D
FollowEvery change as it happens, and a Monday email
Trials
20 active
22 in total · 18 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Talquetamab will be administered SC until disease progression.”In the company’s words, NCT04634552 on ClinicalTrials.gov
- Tested for
- Multiple Myeloma (9 trials), Hematological Malignancies (2 trials), Relapsed/ Refractory Multiple Myeloma
- Main trialPhase 3
- “The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).”In the company’s words, NCT06208150 on ClinicalTrials.gov
- Other names
- JNJ-64407564 · CD3xGPRC5D · Talvey
Other drugs for Multiple Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up7
- 7 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- 30 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 26 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 May 2030Phase 2 trial completes · ClinicalTrials.gov
- 2 Sep 2030Phase 2 trial completes · ClinicalTrials.gov
- 30 Apr 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials22
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 1 Apr 2026 | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | |
| Phase 3Active, not recruiting | 30 Jul 2027 | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | |
| Phase 3Recruiting | 30 Apr 2031 | A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | |
| Phase 2Recruiting | 30 Jun 2027 | A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | |
| Phase 2Active, not recruiting | 26 Aug 2027 | A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma | |
| Phase 2Recruiting | 30 May 2030 | A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events | |
| Phase 2Active, not recruiting | 2 Sep 2030 | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma | |
| Phase 1/2Active, not recruiting | 18 Mar 2025 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | |
| Phase 1Active, not recruiting | 7 Jul 2022 | Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | |
| Phase 1Active, not recruiting | 31 Mar 2025 | A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma | |
| Phase 1Active, not recruiting | 22 May 2025 | A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma | |
| Phase 1Active, not recruiting | 7 Apr 2027 | A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma | |
| Phase 3Withdrawn | 15 Nov 2022 | A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma | |
| Phase 1Completed | 14 Oct 2022 | A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma | |
| Phase 2Authorised | not given | A Phase 2, Multi-cohort Study Applying Innovative MRD Techniques for Transplant Eligible Participants with Previously Untreated Multiple Myeloma - TAURUS | |
| Phase 2Authorised | not given | TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of first line treatment in transplant eligible multiple myeloma patients | |
| Phase 2Authorised | not given | Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01). | |
| Phase 2Authorised | not given | An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab) in the frontline therapy of newly diagnosed high-risk multiple myeloma | |
| Phase 2Authorised | not given | A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-,Talquetamab- and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma | |
| Phase 2Authorised | not given | EFfIcacy and Tolerability of FIXed duration teclistamab and talquetamab FOR FRAIL patients with newly diagnosed multiple myeloma (2 cohort study) - the EMN 37 FITFIX FOR FRAIL trial | |
| Phase 3Authorised | not given | Phase 3 Randomized Study of Teclistamab and Talquetamab (Tec-Tal) Versus Daratumumab and Lenalidomide (DR) in Minimal Residual Disease (MRD) Positive Patients With Newly Diagnosed Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation (TiTan) | |
| Phase 4Authorised | not given | A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026